BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feijóo-Bandín S, Rodríguez-Penas D, García-Rúa V, Mosquera-Leal A, González-Juanatey JR, Lago F. Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level. Endocrine 2016;52:11-29. [PMID: 26662184 DOI: 10.1007/s12020-015-0819-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Kmiecik AM, Dzięgiel P, Podhorska-Okołów M. Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule? Int J Mol Sci 2021;22:8313. [PMID: 34361082 DOI: 10.3390/ijms22158313] [Reference Citation Analysis]
2 Luo JJ, Wen FJ, Qiu D, Wang SZ. Nesfatin-1 in lipid metabolism and lipid-related diseases. Clin Chim Acta 2021;522:23-30. [PMID: 34389280 DOI: 10.1016/j.cca.2021.08.005] [Reference Citation Analysis]
3 Fan Z, Dong J, Mu Y, Liu X. Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway. Bioengineered 2022;13:14670-81. [PMID: 35818327 DOI: 10.1080/21655979.2022.2066748] [Reference Citation Analysis]
4 Aragón-herrera A, Feijóo-bandín S, Abella V, Álvarez L, Roselló-lletí E, Portolés M, Tarazón E, Bigazzi M, Bani D, Gualillo O, González-juanatey JR, Lago F. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue. Pharmacological Research 2019;144:51-65. [DOI: 10.1016/j.phrs.2019.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mikulášková B, Maletínská L, Zicha J, Kuneš J. The role of food intake regulating peptides in cardiovascular regulation. Molecular and Cellular Endocrinology 2016;436:78-92. [DOI: 10.1016/j.mce.2016.07.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
6 Tekin T, Çiçek B, Konyalıgil N, Güntürk İ, Yazıcı C, Karaca Z, Ünlüsavuran M. Increased hip circumference in individuals with metabolic syndrome affects serum nesfatin-1 levels. Postgrad Med J 2020;96:600-5. [DOI: 10.1136/postgradmedj-2019-136887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dotania K, Tripathy M, Rai U. A comparative account of nesfatin-1 in vertebrates. Gen Comp Endocrinol 2021;312:113874. [PMID: 34331938 DOI: 10.1016/j.ygcen.2021.113874] [Reference Citation Analysis]
8 Feijóo-Bandín S, Aragón-Herrera A, Moraña-Fernández S, Anido-Varela L, Tarazón E, Roselló-Lletí E, Portolés M, Moscoso I, Gualillo O, González-Juanatey JR, Lago F. Adipokines and Inflammation: Focus on Cardiovascular Diseases. Int J Mol Sci 2020;21:E7711. [PMID: 33081064 DOI: 10.3390/ijms21207711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Sivri S, Sökmen E, Çelik M, Güçlü K. Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction. Acta Cardiol Sin 2020;36:318-25. [PMID: 32675923 DOI: 10.6515/ACS.202007_36(4).20200207A] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Mirakhor Samani S, Ghasemi H, Rezaei Bookani K, Shokouhi B. SERUM NESFATIN-1 LEVEL IN HEALTHY SUBJECTS WITH WEIGHT-RELATED ABNORMALITIES AND NEWLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS; A CASE-CONTROL STUDY. Acta Endocrinol (Buchar) 2019;-5:69-73. [PMID: 31149062 DOI: 10.4183/aeb.2019.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Ozcan ATD, Altin CB, Erdogan S, Ergin M, Çiftçi A, Kara H, Aksoy SM, But A. The effects of Desflurane and Sevoflurane on Nesfatin-1 levels in laparoscopic Cholecystectomy: a randomized controlled trial. BMC Anesthesiol 2018;18:23. [PMID: 29452603 DOI: 10.1186/s12871-018-0484-x] [Reference Citation Analysis]
12 Kuyumcu A. The relationship between nesfatin-1 and carotid artery stenosis. Scandinavian Cardiovascular Journal 2018;52:328-34. [DOI: 10.1080/14017431.2018.1547840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Serdar Kuyumcu M, Kuyumcu A, Yayla Ç, Bilal Özbay M, Ünal S, Açar B, Nural C, Şenat A, Samur G. The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction. Acta Cardiol Sin 2018;34:386-93. [PMID: 30271088 DOI: 10.6515/ACS.201809_34(5).20180423A] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
14 Tekin T, Cicek B, Konyaligil N. Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian J Med 2019;51:280-4. [PMID: 31692710 DOI: 10.5152/eurasianjmed.2019.18420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Su RY, Geng XY, Yang Y, Yin HS. Nesfatin-1 inhibits myocardial ischaemia/reperfusion injury through activating Akt/ERK pathway-dependent attenuation of endoplasmic reticulum stress. J Cell Mol Med 2021;25:5050-9. [PMID: 33939297 DOI: 10.1111/jcmm.16481] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Feijóo-Bandín S, Aragón-Herrera A, Rodríguez-Penas D, Portolés M, Roselló-Lletí E, Rivera M, González-Juanatey JR, Lago F. Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives. Front Physiol 2017;8:599. [PMID: 28868039 DOI: 10.3389/fphys.2017.00599] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]